A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors

Investigation of Safety of an Investigational Medication Alone or with an Antibody

Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).

Detailed description of study

The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).
Participants will be compensated for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: urothelial carcinoma,non small cell lung cancer
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria
Must have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic
Have adequate organ function
Have a performance status (PS) of less than or equal to on the Eastern Cooperative Oncology Group (ECOG) scale
Have discontinued previous treatments for cancer
Are able to swallow capsules
Exclusion Criteria
Currently enrolled in a clinical study
Have a serious concomitant systemic disorder
Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C
Have a significant cardiac condition
Have previously received an indoleamine- 2,3-dioxygenase (IDO) inhibitor

Updated on 19 Feb 2024. Study ID: 1708847726 (I9L-MC-JZCA)

The purpose of this study is to investigate the safety of an investigational medication when given alone or with an antibody that targets a protein called PD-L1. PD-L1 is involved in the body's immune response, and targeting it can help enhance the body's ability to fight cancer. This study focuses on individuals with advanced or metastatic cancer, which means the cancer has spread to other parts of the body.

Participants in this study will receive either the investigational medication by itself or in combination with the antibody targeting PD-L1. The study will monitor the safety of these treatments and gather information on any side effects. Participants will need to swallow capsules as part of the treatment process.

  • Who can participate: Adults with advanced or metastatic cancer who have stopped previous cancer treatments and have adequate organ function can participate. They must have an ECOG performance status of 1 or less and be able to swallow capsules.
  • Study details: Participants will take the investigational medication alone or with a PD-L1 targeting antibody. A placebo is not used in this study.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here